Research graph
References from Use of cannabidiol products in Canada, United States, Australia, Aotearoa New Zealand, United Kingdom and Germany: products, sources and reasons for use. Local targets link to admitted publications; unresolved targets remain external evidence.
Recreational cannabidiol: Awareness, prevalence of use, and associated factors in a representative sample of the German population
10.1080/10826084.2022.2083175 · 2022 · External reference
Unresolved reference
External reference
Medical cannabis: Regulatory review in United States, European Union and United Kingdom
10.1016/j.jflm.2025.102947 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
The emerging role of cannabidiol (CBD) products; A survey exploring the public's use and perceptions of CBD
10.1002/ptr.7232 · 2021 · External reference
Unresolved reference
External reference
Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials
10.1038/s41386-020-0667-2 · 2020 · External reference
Prevalence of cannabidiol use and correlates in US adults
10.1016/j.dadr.2024.100289 · 2024 · External reference
A cross-sectional study of cannabidiol users
10.1089/can.2018.0006 · 2018 · External reference
Self-reported reasons for medical and nonmedical cannabis use in Australia: A cross-sectional analysis of the International Cannabis Policy Study 2023
10.1016/j.drugalcdep.2026.113124 · 2026 · External reference
Cannabidiol in foods and food supplements: Evaluation of health risks and health claims
10.3390/nu17030489 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Medicinal use of cannabis based products and cannabinoids
2019 · External reference
CBD products that resemble tobacco products enter traditional retail outlets
10.1136/tobaccocontrol-2019-055452 · 2021 · External reference
Usage and health perception of cannabidiol-containing products among the population in Germany: A descriptive study conducted in 2020 and 2021
10.1186/s12889-023-17142-0 · 2023 · External reference
Use and perceptions of cannabidiol products in Canada and in the United States
10.1089/can.2020.0093 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Cannabidiol drug interaction considerations for prescribers and pharmacists
10.1080/17512433.2022.2142114 · 2022 · External reference
Understanding medical cannabis use internationally: Why definitions and context matter
10.1111/add.70117 · 2025 · External reference
Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study
10.1016/j.drugpo.2020.102698 · 2020 · External reference
Unresolved reference
External reference
Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis
10.1016/j.psychres.2024.116049 · 2024 · External reference
Use of internet panels to conduct surveys
10.3758/s13428-015-0617-9 · 2015 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis
10.1016/j.socscimed.2019.06.005 · 2019 · External reference
Beyond the hype-who uses cannabidiol for self-medication–and why: A cross-sectional study in Germany
10.1186/s42238-025-00341-4 · 2025 · External reference
Einstufung von Cannabidiol (CBD) aus Hanf – Ein Betäubungsmittel und damit ein Nicht-Lebensmittel?
2020 · External reference
Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis: S. Lattanzi et al
10.1007/s40265-018-0992-5 · 2018 · External reference
Using cannabis and CBD to sleep: An updated review
10.1007/s11920-024-01564-7 · 2024 · External reference
Expert advice for prescribing cannabis medicines for patients with epilepsy—Drawn from the Australian clinical experience
10.1111/bcp.15262 · 2022 · External reference
Unresolved reference
External reference
Safety and side effects of cannabidiol, a cannabis sativa constituent
10.2174/157488611798280924 · 2011 · External reference
Access to cannabidiol without a prescription: A cross-country comparison and analysis
10.1016/j.drugpo.2020.102935 · 2020 · External reference
Legal and regulatory issues governing cannabis and cannabis-derived products in the United States
10.3389/fpls.2019.00697 · 2019 · External reference
A systematic review of cannabidiol dosing in clinical populations
10.1111/bcp.14038 · 2019 · External reference
Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition
10.1111/dar.13444 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Effectiveness of cannabidiol to manage chronic pain: A systematic review
10.1016/j.pmn.2023.10.002 · 2024 · External reference
Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems
10.1186/s42238-021-00061-5 · 2021 · External reference
Cannabidiol (CBD) products for pain: Ineffective, expensive, and with potential harms
10.1016/j.jpain.2023.10.009 · 2024 · External reference
Cannabidiol for moderate–severe insomnia: A randomized controlled pilot trial of 150 mg of nightly dosing
10.5664/jcsm.10998 · 2024 · External reference
Consumer perception, knowledge, and uses of cannabidiol
10.9740/mhc.2023.10.217 · 2023 · External reference
Odds ratios—Current best practice and use
10.1001/jama.2018.6971 · 2018 · External reference
Medicinal cannabis–The Green Fairy phenomenon
10.1071/ch21001 · 2021 · External reference
Implementation of the medicinal cannabis scheme in New Zealand: six emerging trends
10.26635/6965.6666 · 2024 · External reference
Cannabidiol: A review of clinical efficacy and safety in epilepsy
10.1016/j.pediatrneurol.2019.03.014 · 2019 · External reference
Therapeutic claims in cannabidiol (CBD) marketing messages on Twitter
2021 · External reference
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis
10.1016/j.expneurol.2022.114238 · 2023 · External reference
The effectiveness and safety of cannabidiol in non-seizure-related indications: A systematic review of published randomized clinical trials
10.1007/s40290-022-00446-8 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis
10.1111/add.70360 · 2026 · External reference
CBD (cannabidiol) product attitudes, knowledge, and use among young adults
10.1080/10826084.2020.1729201 · 2020 · External reference
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: A systematic review and meta-analysis
10.1016/s2215-0366(26)00015-5 · 2026 · External reference
Odds ratios—Current best practice and use
10.1001/jama.2018.6971 · ExternalCitation · doi-reference
The emerging role of cannabidiol (CBD) products; A survey exploring the public's use and perceptions of CBD
10.1002/ptr.7232 · ExternalCitation · doi-reference
Using cannabis and CBD to sleep: An updated review
10.1007/s11920-024-01564-7 · ExternalCitation · doi-reference
Efficacy and safety of cannabidiol in epilepsy: A systematic review and meta-analysis: S. Lattanzi et al
10.1007/s40265-018-0992-5 · ExternalCitation · doi-reference
The effectiveness and safety of cannabidiol in non-seizure-related indications: A systematic review of published randomized clinical trials
10.1007/s40290-022-00446-8 · ExternalCitation · doi-reference
Prevalence of cannabidiol use and correlates in US adults
10.1016/j.dadr.2024.100289 · ExternalCitation · doi-reference
Self-reported reasons for medical and nonmedical cannabis use in Australia: A cross-sectional analysis of the International Cannabis Policy Study 2023
10.1016/j.drugalcdep.2026.113124 · ExternalCitation · doi-reference
Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study
10.1016/j.drugpo.2020.102698 · ExternalCitation · doi-reference
Access to cannabidiol without a prescription: A cross-country comparison and analysis
10.1016/j.drugpo.2020.102935 · ExternalCitation · doi-reference
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis
10.1016/j.expneurol.2022.114238 · ExternalCitation · doi-reference
Medical cannabis: Regulatory review in United States, European Union and United Kingdom
10.1016/j.jflm.2025.102947 · ExternalCitation · doi-reference
Cannabidiol (CBD) products for pain: Ineffective, expensive, and with potential harms
10.1016/j.jpain.2023.10.009 · ExternalCitation · doi-reference
Cannabidiol: A review of clinical efficacy and safety in epilepsy
10.1016/j.pediatrneurol.2019.03.014 · ExternalCitation · doi-reference
Effectiveness of cannabidiol to manage chronic pain: A systematic review
10.1016/j.pmn.2023.10.002 · ExternalCitation · doi-reference
Therapeutic potential of cannabidiol (CBD) in anxiety disorders: A systematic review and meta-analysis
10.1016/j.psychres.2024.116049 · ExternalCitation · doi-reference
Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms: Systematic review and meta-analysis
10.1016/j.socscimed.2019.06.005 · ExternalCitation · doi-reference
The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: A systematic review and meta-analysis
10.1016/s2215-0366(26)00015-5 · ExternalCitation · doi-reference
Adverse effects of cannabidiol: A systematic review and meta-analysis of randomized clinical trials
10.1038/s41386-020-0667-2 · ExternalCitation · doi-reference
Medicinal cannabis–The Green Fairy phenomenon
10.1071/ch21001 · ExternalCitation · doi-reference
CBD (cannabidiol) product attitudes, knowledge, and use among young adults
10.1080/10826084.2020.1729201 · ExternalCitation · doi-reference
Recreational cannabidiol: Awareness, prevalence of use, and associated factors in a representative sample of the German population
10.1080/10826084.2022.2083175 · ExternalCitation · doi-reference
Cannabidiol drug interaction considerations for prescribers and pharmacists
10.1080/17512433.2022.2142114 · ExternalCitation · doi-reference
A cross-sectional study of cannabidiol users
10.1089/can.2018.0006 · ExternalCitation · doi-reference
Use and perceptions of cannabidiol products in Canada and in the United States
10.1089/can.2020.0093 · ExternalCitation · doi-reference
Understanding medical cannabis use internationally: Why definitions and context matter
10.1111/add.70117 · ExternalCitation · doi-reference
The prevalence of cannabidiol (CBD) use in North America and Europe: A meta-analysis
10.1111/add.70360 · ExternalCitation · doi-reference
A systematic review of cannabidiol dosing in clinical populations
10.1111/bcp.14038 · ExternalCitation · doi-reference
Expert advice for prescribing cannabis medicines for patients with epilepsy—Drawn from the Australian clinical experience
10.1111/bcp.15262 · ExternalCitation · doi-reference
Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition
10.1111/dar.13444 · ExternalCitation · doi-reference
CBD products that resemble tobacco products enter traditional retail outlets
10.1136/tobaccocontrol-2019-055452 · ExternalCitation · doi-reference
Usage and health perception of cannabidiol-containing products among the population in Germany: A descriptive study conducted in 2020 and 2021
10.1186/s12889-023-17142-0 · ExternalCitation · doi-reference
Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems
10.1186/s42238-021-00061-5 · ExternalCitation · doi-reference
Beyond the hype-who uses cannabidiol for self-medication–and why: A cross-sectional study in Germany
10.1186/s42238-025-00341-4 · ExternalCitation · doi-reference
Safety and side effects of cannabidiol, a cannabis sativa constituent
10.2174/157488611798280924 · ExternalCitation · doi-reference
Implementation of the medicinal cannabis scheme in New Zealand: six emerging trends
10.26635/6965.6666 · ExternalCitation · doi-reference
Legal and regulatory issues governing cannabis and cannabis-derived products in the United States
10.3389/fpls.2019.00697 · ExternalCitation · doi-reference
Cannabidiol in foods and food supplements: Evaluation of health risks and health claims
10.3390/nu17030489 · ExternalCitation · doi-reference
Use of internet panels to conduct surveys
10.3758/s13428-015-0617-9 · ExternalCitation · doi-reference
Cannabidiol for moderate–severe insomnia: A randomized controlled pilot trial of 150 mg of nightly dosing
10.5664/jcsm.10998 · ExternalCitation · doi-reference
Consumer perception, knowledge, and uses of cannabidiol
10.9740/mhc.2023.10.217 · ExternalCitation · doi-reference
